[HTML][HTML] Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective …
L Monin, AG Laing, M Muñoz-Ruiz… - The Lancet …, 2021 - thelancet.com
Background The efficacy and safety profiles of vaccines against SARS-CoV-2 in patients
with cancer is unknown. We aimed to assess the safety and immunogenicity of the …
with cancer is unknown. We aimed to assess the safety and immunogenicity of the …
[引用][C] Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational …
L Monin, AG Laing, M Muñoz-Ruiz… - The Lancet …, 2021 - produccioncientifica.ucm.es
Background: The efficacy and safety profiles of vaccines against SARS-CoV-2 in patients
with cancer is unknown. We aimed to assess the safety and immunogenicity of the …
with cancer is unknown. We aimed to assess the safety and immunogenicity of the …
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
L Monin, AG Laing, M Muñoz-Ruiz… - The Lancet …, 2021 - pubmed.ncbi.nlm.nih.gov
Background The efficacy and safety profiles of vaccines against SARS-CoV-2 in patients
with cancer is unknown. We aimed to assess the safety and immunogenicity of the …
with cancer is unknown. We aimed to assess the safety and immunogenicity of the …
[HTML][HTML] Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective …
L Monin, AG Laing, M Muñoz-Ruiz… - The Lancet …, 2021 - ncbi.nlm.nih.gov
Background The efficacy and safety profiles of vaccines against SARS-CoV-2 in patients
with cancer is unknown. We aimed to assess the safety and immunogenicity of the …
with cancer is unknown. We aimed to assess the safety and immunogenicity of the …
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study.
L Monin, AG Laing, M Muñoz-Ruiz… - The Lancet …, 2021 - europepmc.org
Background The efficacy and safety profiles of vaccines against SARS-CoV-2 in patients
with cancer is unknown. We aimed to assess the safety and immunogenicity of the …
with cancer is unknown. We aimed to assess the safety and immunogenicity of the …
[HTML][HTML] Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective …
L Monin, AG Laing, M Muñoz-Ruiz… - The Lancet …, 2021 - thelancet.com
Background The efficacy and safety profiles of vaccines against SARS-CoV-2 in patients
with cancer is unknown. We aimed to assess the safety and immunogenicity of the …
with cancer is unknown. We aimed to assess the safety and immunogenicity of the …
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study.
L Monin, AG Laing, M Muñoz-Ruiz, DR McKenzie… - 2021 - crick.figshare.com
BACKGROUND: The efficacy and safety profiles of vaccines against SARS-CoV-2 in
patients with cancer is unknown. We aimed to assess the safety and immunogenicity of the …
patients with cancer is unknown. We aimed to assess the safety and immunogenicity of the …
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study.
L Monin, AG Laing, M Muñoz-Ruiz, DR McKenzie… - 2021 - cabidigitallibrary.org
Background: The efficacy and safety profiles of vaccines against SARS-CoV-2 in patients
with cancer is unknown. We aimed to assess the safety and immunogenicity of the …
with cancer is unknown. We aimed to assess the safety and immunogenicity of the …
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
L Monin, AG Laing, M Muñoz-Ruiz… - The Lancet …, 2021 - kclpure.kcl.ac.uk
BACKGROUND: The efficacy and safety profiles of vaccines against SARS-CoV-2 in
patients with cancer is unknown. We aimed to assess the safety and immunogenicity of the …
patients with cancer is unknown. We aimed to assess the safety and immunogenicity of the …
[引用][C] Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational …
L Monin, AG Laing, M Muñoz-Ruiz, DR McKenzie… - The Lancet …, 2021 - cir.nii.ac.jp
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for
patients with cancer: interim analysis of a prospective observational study | CiNii Research …
patients with cancer: interim analysis of a prospective observational study | CiNii Research …